Loading company…
Poxel develops treatments for chronic metabolic diseases, including type 2 diabetes and NASH.
Founded in 2009, Poxel is based in Lyon, France, and develops treatments for chronic metabolic diseases. Its portfolio includes candidates for NASH and rare metabolic diseases, as well as TWYMEEG®, approved in Japan for type 2 diabetes in 2021. In November 2024, OrbiMed Advisors agreed to provide USD 50 million in non-dilutive financing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in